Skip to main content
OpenTrials
Completed

NCT Number: NCT03079336

Implementation of Psychological Treatment in Generalized Anxiety

Pragmatic randomized controlled trial (expected N = 80) of cognitive-behavioral therapy (CBT) to contrast two psychotherapeutic implementation strategies (State-of-the-Art welcome phase vs. prolonged focus on sudden changes). Blinded allocation of implementation strategy for patients; open label for therapists (no blinding possible), randomized allocation for patients, therapist allocation via ABAB-design (crossed-therapist design). Post treatment self-reported outcome will be measured based on a latent outcome factor (i. e. "outcome composite").

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Department of Psychology, University of Zürich

Zurich, 8050, Switzerland

About this study

State of research. The proposed trial has a common theme, i.e., the understanding of the enduring efficacy of psychological treatments in individuals who suffer from general anxiety disorder (GAD). There is meta-analytic evidence that bona fide psychotherapy is an effective treatment for GAD, but also for individuals that suffers from anxiety and depression. Nonetheless, in spite of the empirical evidence of the overall efficacy, there is a lack of randomized controlled studies that systematically investigate the therapists' variability (i. e. therapist effects) within the very same treatment protocol. The development of study designs to investigate potential health professional effects along treatment effects is a general claim for human interventions. This protocol includes one of the very first process-outcome trials in GAD that systematically examine theory-based patients' and therapists' characteristics simultaneously using longitudinal multilevel methodology.

Along with investigating therapist and patient characteristics, two methods for timing the check-in phase at the beginning of each session will be compared by keeping constant the standardized treatment manual for patients with GAD: (a) prolonged focus on subtle changes check-in condition lasting from 7 to 20 minutes and (b) a state of the art (SOA) check-in phase lasting from 5 to 10 minutes. To address the nested data structure, therapists will be allocated by a single-subject ABAB-design. A total of 80 patients (40 participants in each of the two conditions) with a primary GAD diagnosis will be treated by 20 advanced cognitive-behavioral therapy trainees at the psychotherapy outpatient clinic in the department of psychology at the university of Zürich.

Relevance. (a) Study population. GAD is a neglected disorder in the Swiss mental health system. GAD is associated with personal suffering, a reduced quality of life, and high economic costs. (b) Design development. Systematic integration of potential therapist effects is a neglected aspect in many areas of evidence-based human interventions (inside but also outside of psychological interventions). (c) Treatment development. Evidence-based treatments are usually far from being fully efficacious. There is a debate about innovative research agendas and how to foster the efficacy of such treatments. (d) Experimental process-outcome research. There is a need for future research to investigate theory-based therapist effects and in-session timing within rigorous experimental process-outcome research designs to better understand the factors involved in therapeutic change (e.g. http://www.nature.com/news/therapy-deficit-1.11477).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • fulfill the diagnostic criteria for GAD based on the structured interview for DSM,
  • are 18 years of age or older,
  • Mastery of German language
  • are seeking out a cognitive-behavioral therapy (CBT) for GAD at the outpatient clinic (Attenhoferstrasse 9) of the Institute for Psychology of the University of Zürich
  • Informed consent as documented by signature

Exclusion criteria

  • Acute Suicidal Ideation (BDI Suicide item > 1 or suicidal ideation in the telephone interview)
  • Currently taking a psychotic or bipolar disorder medication, or
  • Currently receiving treatment from a professional psychotherapist/psychiatrist.

Treatment and study plan

Implementation - SOTA

Behavioral

The implementation of an evidence-based treatment is largely principle-based - allowing considerable therapeutic flexibility in determining and timing of different treatment aspects. In this condition progress, subtle changes and sudden gains may be an explicit topic and there is no restraint to avoid such topics. However, the therapists are not obligated to take a systematized focus on potential subtle changes and they may use the timing of the sessions to involve the patients into the other tasks of therapy.

Implementation - Prolonged focus on changes

Behavioral

Systematized sequence of exploration of subtle changes at a prolonged check-in phase: (1) the precise change situation, (2) related emotional states, (3) related helpful thoughts and self-verbalizations, (4) reinforcement of generalized self-efficacy and treatment motivation, (5) benefit for the upcoming session goals (Flückiger, Grosse Holtforth, et al. 2013, 2014).

Mastery your Anxiety and Worry (MAW)

Behavioral

In the present study, the MAW-packet will be applied within a usual 16-session individual therapy format and up to 3 further booster sessions.

The session format of 50-60 minute usually consists of (a) a check-in phase of 5 to 15 minutes that includes a patients welcoming, reviewing self-help and agenda setting, (b) a working phase around 35-45 minutes that focuses on the previously agreed session goals, (c) a feedback phase of 5 to 10 minutes that summarizes the session and previews the upcoming self-help assignment.

Other names: Cognitive Behavioral Therapy

Primary outcomes

  1. Change from baseline to 6 months treatment completion of a latent 5-facet, self-report outcome-factor

    Time frame: Baseline, treatment completion after 6 months (16 sessions)

    Latent factor of the below-mentioned 5 self-report questionnaires (outcome composite)

Other outcomes

  1. Penn State Worry Questionnaire [PSWQ]

    Time frame: Baseline, treatment completion after 6 months (16 sessions)

    Self-report worry inventory (Meyer et al., 1990)

  2. Beck Anxiety Inventory [BAI]

    Time frame: Baseline, treatment completion after 6 months (16 sessions)

    Self-report anxiety inventory (Beck et al., 1988)

  3. Beck Depression Inventory II [BDI-II]

    Time frame: Baseline, treatment completion after 6 months (16 sessions)

    Self-report depression inventory (Beck et al., 1996)

  4. Short version of the Symptom Check List [SCL-9]

    Time frame: Baseline, treatment completion after 6 months (16 sessions)

    Self-report symptom severity index (Klaghofer & Brähler, 2001)

  5. Short version of the Resource Self-Report Questionnaire [RES]

    Time frame: Baseline, treatment completion after 6 months (16 sessions)

    Self-report resource inventory (Troesken & Grawe, 2004)

Sponsors and collaborators

Lead sponsor

University of Zurich

Other

Registry information

Official study title

Design Development in Randomized Clinical Trials - Psychological Treatment in Generalized Anxiety

Acronym: IMPLEMENT2_0

Important dates

Study start
2017
Primary completion
2022
Study completion
2022
First posted
Mar 14, 2017
Registry last updated
May 26, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.